



March 20, 2019

Dear Pharmacist,

RE: RESTASIS MultiDose® Temporary Supply Disruption

As a Health Care Provider, Allergan Inc. would like to make you aware that we are experiencing temporary manufacturing constraints with RESTASIS MultiDose®, which is expected to be resolved in the near future.

To maintain patient care, RESTASIS® treatment can be continued with Single-unit Vials during the temporary supply disruption.

Product Description		Size	DIN	Item	UPC	Status
P ^r RESTASIS® Multidose 0.05% Oph Emuls	cyclosporine	5.5ml	02476835	95301EC	0 69886 95301 5	Stock Outage
P ^r RESTASIS® 0.05% Oph Emuls	cyclosporine	30 x 0.4 mL	02355655	93346EC	0 6988693346 8	Stock Available
P ^r RESTASIS® 0.05% Oph Emuls	cyclosporine	60 x 0.4 mL	02355655	94529EC	0 6988694529 4	Stock Available

Allergan posted a shortage notice on the [Drug Shortages Canada](#) website on Friday, February 1, 2019, to notify Health Care Providers. We will ensure supply recovery dates are updated on the website as new information becomes available.

We recommend that you make your RESTASIS MultiDose® patients aware of the situation, and reassure patients that Allergan is working to resolve the situation to ensure patient access to medication is restored.

Should you have any questions or concerns, or if you require additional information please do not hesitate to contact me.

Yours sincerely,

Allergan Inc.

Fiona McCloskey,
Business Unit Director
Eyecare & GI

Allergan Inc.

85 Enterprise Boulevard, Suite 500
Markham, ON L6G 0B5

T 905 940 1660
F 905 940 1902
www.allergan.ca